BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32226541)

  • 21. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L; Fan Z; Du G; Wang H
    Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.
    Kato A; Ng S; Thangasamy A; Han H; Zhou W; Raeppel S; Fallon M; Guha S; Ammanamanchi S
    Mol Carcinog; 2021 Nov; 60(11):734-745. PubMed ID: 34347914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
    Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
    Int J Cancer; 2019 Sep; 145(6):1529-1537. PubMed ID: 30801702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer.
    Liu YF; Luo D; Li X; Li ZQ; Yu X; Zhu HW
    Pancreas; 2021 Feb; 50(2):227-234. PubMed ID: 33565800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear GRP78 Promotes Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Ductal Adenocarcinoma.
    Zhao T; Jiang T; Li X; Chang S; Sun Q; Kong F; Kong X; Wei F; He J; Hao J; Xie K
    Clin Cancer Res; 2023 Dec; 29(24):5183-5195. PubMed ID: 37819952
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
    Waters JA; Matos J; Yip-Schneider M; Aguilar-Saavedra JR; Crean CD; Beane JD; Dumas RP; Suvannasankha A; Schmidt CM
    Surgery; 2015 Oct; 158(4):881-8; discussion 888-9. PubMed ID: 26209568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation.
    Guo Y; Xiao Y; Guo H; Zhu H; Chen D; Wang J; Deng J; Lan J; Liu X; Zhang Q; Bai Y
    Aging (Albany NY); 2021 Jul; 13(14):18545-18563. PubMed ID: 34320467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
    Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
    Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
    Sumiyoshi H; Matsushita A; Nakamura Y; Matsuda Y; Ishiwata T; Naito Z; Uchida E
    Oncol Rep; 2016 Jun; 35(6):3216-26. PubMed ID: 27035235
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Liu M; Zhang Y; Yang J; Cui X; Zhou Z; Zhan H; Ding K; Tian X; Yang Z; Fung KA; Edil BH; Postier RG; Bronze MS; Fernandez-Zapico ME; Stemmler MP; Brabletz T; Li YP; Houchen CW; Li M
    Gastroenterology; 2020 Feb; 158(3):679-692.e1. PubMed ID: 31711924
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signal-transducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth.
    Lang SA; Moser C; Gaumann A; Klein D; Glockzin G; Popp FC; Dahlke MH; Piso P; Schlitt HJ; Geissler EK; Stoeltzing O
    Clin Cancer Res; 2007 Nov; 13(21):6459-68. PubMed ID: 17975158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
    Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
    Wang R; Cheng L; Xia J; Wang Z; Wu Q; Wang Z
    Curr Cancer Drug Targets; 2014; 14(4):407-17. PubMed ID: 24575976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
    Zhang X; Zhao P; Wang C; Xin B
    Biochem Biophys Res Commun; 2019 Mar; 510(4):508-514. PubMed ID: 30737032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells.
    Xu S; Yu C; Ma X; Li Y; Shen Y; Chen Y; Huang S; Zhang T; Deng W; Wang Y
    Eur J Pharmacol; 2021 Mar; 894():173817. PubMed ID: 33345849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia Inducible Factor 1 (HIF-1) Recruits Macrophage to Activate Pancreatic Stellate Cells in Pancreatic Ductal Adenocarcinoma.
    Li N; Li Y; Li Z; Huang C; Yang Y; Lang M; Cao J; Jiang W; Xu Y; Dong J; Ren H
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27271610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
    Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
    EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.